Skip to content
DataLookout
Menu

NCT01906385

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

StatusActive, Not Recruiting
PhasePhase 1/2
SponsorCerenome
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 33 versions: 28 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Site details revised at 4 of 4 sites
  2. Notable Primary and study completion pushed from Dec 2025 to Apr 2027 Show 5 more changesShow less
    • Lead sponsor: Plus Therapeutics to Cerenome
    • Eligibility criteria expanded, about 45 words
    • Study sites: 3 to 4
    • Secondary endpoints: details revised at 2 of 9 entries
    • Publications: details revised at 1 of 1 entry
  3. Notable Primary and study completion dates: Jan 2025 to Dec 2025
    • Site contacts updated at 1 of 3 sites
    v31
  4. Minor Study sites: 2 to 3v30
  5. Minor Study sites: 3 to 2v29
Show 22 earlier versionsHide 22 earlier versions
  1. Minor Site contacts updated at 1 of 3 sitesv27
  2. Notable Eligibility criteria expanded, about 162 words
    • Primary endpoints: 1 to 2
    • Secondary endpoints: 3 to 9
    • Study description expanded, about 96 words
    v25
  3. Notable Eligibility criteria expanded, about 8 words
    • Study description expanded, about 128 words
    • Site contacts updated at 1 of 3 sites
    v23
  4. Minor Site contacts updated at 1 of 3 sitesv22
  5. Minor Site details revised at 1 of 3 sitesv21
  6. Minor Site details revised at 1 of 3 sitesv20
  7. Minor Site details revised at 1 of 3 sitesv19
  8. Minor Site contacts updated at 2 of 3 sitesv18
  9. Minor Study title expanded, about 1 wordv17
  10. Minor Site details revised at 1 of 3 sitesv16
  11. Notable Lead sponsor: The University of Texas Health Science Center at San Antonio to Plus Therapeuticsv15
  12. Notable Lead sponsor: Andrew Brenner to The University of Texas Health Science Center at San Antoniov14 Show 5 more changesShow less
    • Enrollment target: 30 to 55
    • Eligibility criteria expanded, about 12 words
    • Study sites: 1 to 3
    • Secondary endpoints: details revised at 1 of 3 entries
    • Collaborators expanded, about 4 words
  13. Notable Primary and study completion dates: Jan 2020 to Jan 2025v13 Show 4 more changesShow less
    • Start date: Mar 2015 to Jun 3, 2015
    • Eligibility criteria expanded, about 58 words
    • Study description shortened, about 327 words
    • Study title revised
  14. Notable Primary and study completion dates: Jan 2019 to Jan 2020v12
  15. Minor Primary and study completion dates pushed to Jan 2019v11
  16. Minor Interventions: Rhenium Liposome Treatment (Radiation) to Rhenium Liposome Treatment (Drug)v10
  17. Notable Primary completion date: Aug 2017 to Aug 2018
    • Study completion date: Dec 2017 to Dec 2018
    v9
  18. Minor Primary completion date: Mar 2017 to Aug 2017v8
  19. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v5
  20. Notable Start date: Dec 2014 to Mar 2015v4
  21. Notable Start date: Mar 2014 to Dec 2014
    • Study arms: 0 to 1
    v3
  22. Notable Start date: Oct 2013 to Mar 2014
    • Primary completion date: Oct 2016 to Mar 2017
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Phase 1: Maximum Tolerated Dose
Timeframe: 90 days
Phase 2: Overall Survival
Timeframe: 12 Months

Secondary (9)

Phase 1: Dose Distribution
Phase 1: Response rate
Phase 1: Survival
Phase 1: Safety of single dose of treatment
Phase 2: Safety and tolerability of 186RNL
Show 4 moreShow less
Phase 2: Objective response rate (ORR)
Phase 2: Progression free survival at 6 months (PFS-6)
Phase 2: Progression free survival (PFS) from the initiation of study to first documented progression
Phase 2: Quality of Life

Arms and interventions

186Rhenium Liposome TreatmentExperimental

Arm Phase I: Experimental: Dose Escalation for Cohorts 1-8 Each participant will receive a single administration of 186RNL. At each dose level, a minimum of three to a maximum of six participants will be enrolled. If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment. The dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below: COHORT ACTIVITY Cohort 1 (1.0 mCi) Cohort 2 (2.0 mCi) Cohort 3 (4.0 mCi) Cohort 4 (8.0 mCi) Cohort 5 (13.4 mCi) Cohort 6 (22.3 mCi) Cohort 7 (31.2 mCi) Cohort 8 (41.5 mCi) Phase 2: Single arm, prospective study utilizing a non-DLT dose obtained from the dose escalation portion of IND 116117, NIH-NCI Grant (22.3 mCi (total 186RNL activity) at a concentration of 2.5 mCi/mL and 8.8 mL total volume).

Drugs: Rhenium Liposome Treatment

Sites

4 sites in 1 country